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ABSTRACT
The African Union Bureau of Heads of State and 
Government endorsed the COVID- 19 Vaccine Development 
and Access Strategy to vaccinate at least 60% of each 
country’s population with a safe and efficacious vaccine 
by 2022, to achieve the population- level immunity 
needed to bring the pandemic under control. Using 
publicly available, country- level population estimates and 
COVID- 19 vaccination data, we provide unique insights 
into the uptake trends of COVID- 19 vaccinations in the 15 
countries that comprise the Economic Community of West 
Africa States (ECOWAS). Based on the vaccination rates 
in the ECOWAS region after three months of commencing 
COVID- 19 vaccinations, we provide a projection of the 
trajectory and speed of vaccination needed to achieve a 
COVID- 19 vaccination coverage rate of at least 60% of 
the total ECOWAS population. After three months of the 
deployment of COVID- 19 vaccines across the ECOWAS 
countries, only 0.27% of the region’s total population 
had been fully vaccinated. If ECOWAS countries follow 
this trajectory, the sub- region will have less than 1.6% 
of the total population fully vaccinated after 18 months 
of vaccine deployment. Our projection shows that to 
achieve a COVID- 19 vaccination coverage of at least 60% 
of the total population in the ECOWAS sub- region after 9, 
12 and 18 months of vaccine deployment; the speed of 
vaccination must be increased to 10, 7 and 4 times the 
current trajectory, respectively. West African governments 
must deploy contextually relevant and culturally 
acceptable strategies for COVID- 19 vaccine procurements, 
distributions and implementations in order to achieve 
reasonable coverage and save lives, sooner rather than 
later.
INTRODUCTION
The unparalleled speed of development of 
COVID- 19 vaccines demonstrates humani-
ty’s resilience, ingenuity and cooperation in 
overcoming challenges. The acceptance and 
high uptake of COVID- 19 vaccines are vital to 
attaining sufficient immunisation coverage to 
control the pandemic. A recent study across 
10 low- income and middle- income coun-
tries (LMICs) reported significantly higher 
COVID- 19 vaccine acceptance on average 
(80.3%), compared with the USA (64.6%) 
and Russia (30.4%).1 These findings suggest 
that prioritising vaccine distribution to the 
global South would help to ensure greater 
Summary box
 ► The unparalleled speed at which the COVID- 19 vac-
cines were developed brought a renewed hope that 
the acute phase of the pandemic was almost over, 
but the inequitable global distribution of the vaccines 
has contributed to the emergence of mutant strains.
 ► The African Union Bureau of Heads of State and 
Government endorsed the COVID- 19 Vaccine 
Development and Access Strategy with the goal of 
vaccinating at least 60% of each country’s popu-
lation with safe and efficacious vaccines by 2022, 
to achieve the population- level immunity needed to 
bring the pandemic under control.
 ► Literature documenting vaccine uptake and the tra-
jectory needed to achieve full vaccination at a sub- 
regional or country- level is scanty.
 ► Using publicly available data, we provide context- 
specific information on full COVID- 19 vaccination 
rates after 3 months of vaccine deployment in West 
Africa and describe the trajectory needed to achieve 
a full COVID- 19 vaccination coverage rate of at least 
60% of the total population in West Africa.
 ► This information will help to guide future plans for 
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population coverage and accelerate global efforts to end 
the acute phase of the COVID- 19 pandemic.
The inadequate global coverage of COVID- 19 vaccines, 
with approximately 60% of people in high- income coun-
tries (HICs) receiving at least one dose of a COVID- 19 
vaccine by 15 September 2021, compared with a paltry 3% 
of people in Africa2 could potentially trigger the emer-
gence of mutant strains that could render the vaccines 
less effective. Many stakeholders have vehemently crit-
icised this glaring inequality as causing a dangerous 
divergence in COVID- 19 survival rates,3 with the world 
described as being ‘on the brink of a catastrophic moral 
failure’.4 Despite the recent sharing of excess COVID- 19 
vaccines by wealthy countries, the inequity gap remains 
very wide as nearly 90% of African countries were unable 
to vaccinate 10% of their populations by the end of 
September 2021.5
Besides these disturbing developments, variations exist 
in the COVID- 19 epidemiology and vaccination imple-
mentation within the African sub- regions. For example, 
West Africa accounts for 10% of the confirmed cases 
and 5% of the total deaths recorded in Africa, compared 
with other African sub- regions such as South, North and 
East Africa with higher proportions of confirmed cases 
and deaths.6 The relatively low numbers of confirmed 
COVID- 19 cases and deaths in West Africa appear to 
have created an optimistically biased perception of self- 
protection from SARS- CoV- 2 infection by a substantial 
population of West African inhabitants. This perception 
manifests itself in widespread vaccine hesitancy and low 
uptake of the COVID- 19 vaccines in many West African 
countries.7–10
Most publications on COVID- 19 vaccinations in Africa 
have focused on preparedness, hesitancy, and manufac-
turing capacity,9–11 while literature documenting vaccine 
uptake at a sub- regional or country- level is scanty. Given 
the heterogeneity in COVID- 19 vaccination implementa-
tion across African countries, a need exists to set up a 
monitoring framework to track the progress of COVID- 19 
vaccination programmes at sub- regional levels in order to 
provide robust, context- specific information that could 
guide future implementations of COVID- 19 vaccinations 
in the sub- region. This article aims to provide unique 
insights into the trends in uptake of COVID- 19 vaccines 
in the 15 countries that comprise the Economic Commu-
nity of West Africa States (ECOWAS), using publicly avail-
able and country- specific COVID- 19 vaccination data. 
The secondary objective of this study is to forecast the 
trajectory of COVID- 19 vaccinations in the 15 ECOWAS 
countries to determine their vaccination performance 
against the target of vaccinating at least 60% of the popu-
lation by 2022.12
BACKGROUND TO DATA CURATION
We conducted a retrospective, multi- country analysis of 
national COVID- 19 vaccination coverage and uptake 
among the overall population in the 15 ECOWAS 
countries, from the time of inception of vaccine roll- out 
until three months after deployment of COVID- 19 vacci-
nations in each country. The ECOWAS is an alliance 
whose aim is to promote regional integration and visa- 
free trans- border migration for all West Africans.13 The 
15- member regional bloc comprises Benin, Burkina Faso, 
Cape Verde, Côte d'Ivoire, The Gambia, Ghana, Guinea, 
Guinea Bissau, Liberia, Mali, Niger, Nigeria, Senegal, 
Sierra Leone and Togo.
According to the latest UN estimates, the popula-
tion of the countries of the member states of ECOWAS 
was 410 million, on 1 September 2021, accounting for 
about 5% of the world population.14 All 15 countries of 
ECOWAS are part of the 92 LMICs eligible to participate 
in the COVAX Facility supported by the COVAX Advance 
Market Commitment, an innovative funding mechanism 
established to enable Gavi to subsidise vaccine purchase 
through the COVAX Facility for resource- constrained 
countries.15 In addition, by belonging to the African 
Union, the 15 countries of ECOWAS also benefit from 
COVID- 19 vaccine allocations by the Africa Vaccine 
Acquisition Task Team (AVATT).16 Individual countries 
in West Africa also received COVID- 19 vaccines as dona-
tions from bilateral partners.6
DATA SOURCES AND ANALYSIS
We extracted COVID- 19 vaccination data obtained from 
the country vaccination implementation teams in West 
Africa through the WHO Africa COVID- 19 Vaccination 
Dashboard6 and Our World in Data’s COVID- 19 Data 
Explorer.17 We also obtained data on the dates when each 
country received the first shipment of the vaccines, dates 
each country started vaccinations, the vaccine types, and 
their sources from the WHO Africa COVID- 19 Vaccina-
tion Dashboard.6 From the UN World Population Pros-
pects 2020, we extracted data on the population in each 
of the 15 West African countries.14 Given the ad- hoc 
implementations of COVID- 19 vaccinations across many 
ECOWAS countries in which the vaccinations were prior-
itised for political leaders and top government officials 
alongside front- line healthcare workers; and in other 
instances, where COVID- 19 vaccinations were opened up 
to all persons above 18 years who were willing to receive 
the vaccines18; it was impracticable to obtain reliable and 
accurate proportions of the populations targeted for the 
first phase of the vaccinations, hence we did not include 
these data in our analysis.
All statistical analyses were conducted using the R 
Statistical Software.19 Descriptive and regression analyses 
were performed, and the results were presented by vacci-
nation performance at ECOWAS and country levels.
ESTIMATING COVID-19 VACCINATION COVERAGE TRENDS
We estimated COVID- 19 vaccination uptake and coverage 
by tracking the number of people who received a first 
dose of the vaccine (COV- 1) and those who received 
a second dose, that is, those who were fully vaccinated 
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(COV- 2), and calculated the proportion of people who 
received at least one dose of a COVID- 19 vaccine based 
on each country’s total population. We computed the 
proportion of people vaccinated in the West African sub- 
region by dividing the total vaccinated by the total popu-
lation across the 15 countries included.
DETERMINING VACCINATION TRAJECTORY FROM VACCINATION 
RATES
On 20 August 2020, the African Union Bureau of Heads 
of State and Government endorsed the COVID- 19 
Vaccine Development and Access Strategy with the goal 
of vaccinating at least 60% of each country’s population 
with safe and efficacious vaccines by 2022, to achieve the 
population- level immunity needed to bring the pandemic 
under control.12 To achieve this target, we projected the 
kinetics of vaccinating at least 60% of the entire ECOWAS 
population and for each country of ECOWAS. We 
conducted a simple linear interpolation to compute the 
COVID- 19 vaccination rates in the 15 ECOWAS countries. 
The first day in the analysis was the day when vaccinations 
started in a particular country, making the calculations 
not dependent on the calendar time, thereby facilitating 
across country computations. Although many factors 
may affect the vaccination rates in a country, the anal-
ysis considered a simple linear relationship between the 
days and vaccination coverage. In other words, the task 
of calculating the rate at which vaccine coverage should 
increase over the coming months in order to reach a 
targeted vaccine coverage can still be achieved with the 
simple linear model, assuming the factors or conditions 
needed are met. We calculated the initial slope as the rate 
of change in the vaccination coverage from the first day 
of the vaccine roll- out until three months, after vaccine 
roll- out in each ECOWAS country. We estimated the vacci-
nation rates based on the average vaccination rate in each 
of the 15 ECOWAS countries (ie, slope estimate based on 
the average value over the 15 ECOWAS countries). We 
also computed the pace of vaccine coverage required to 
achieve vaccine targets in each of the countries, as well 
as the entire 15 ECOWAS countries using simple linear 
regression (see online supplemental appendix for model 
details and examples). Subsequently, we calculated the 
projections for vaccination trends to achieve 50%, 60% 
and 70% vaccination coverages at 9, 12 and 18 months 
since first vaccine roll- out.
FINDINGS OF THE ANALYSIS OF THE DATASETS
Senegal was the first country in West Africa to receive 
COVID- 19 vaccines through the COVAX facility on 17 
February 2021. This was followed by Sierra Leone, Ghana 
and Côte d'Ivoire, which received their first supplies on the 
18 February 2021, 24 February 2021 and 26 February 2021, 
respectively (figure 1A). Burkina Faso was the last West 
African country to receive vaccine supplies through the 
COVAX Facility on 30 May 2021. The number of initial doses 
received ranged from 24 000 doses in Cape Verde with a total 
population of 556 000 people to 3.9 million doses in Nigeria 
with 211 million people (figure 1B and table 1).
The first set of West African countries to deploy their 
COVID- 19 vaccines included Senegal, Ghana, Côte 
d'Ivoire and Nigeria on 22 February 2021, 1 March 2021, 
1 March 2021 and 4 March 2021, respectively (figure 1A). 
The time from the arrival of vaccines to deployment was 
as short as two days in Nigeria and Togo and as long as 
25 and 27 days in Liberia and Sierra Leone, respectively 
(table 1). The most common type of COVID- 19 vaccines 
that was initially delivered through the COVAX Facility 
to all West African countries was the two- dose Covishield 
vaccine (Oxford Astrazeneca), however, Sinopharm and 
Sinovac vaccines were also received (figure 1B).
Overall, after three months of the deployment of 
COVID- 19 vaccinations across all ECOWAS countries, 
only 0.27% of the total population of the region had 
Figure 1 (A) Timelines of COVID- 19 vaccine arrivals and deployments in I5 ECOWAS countries. (B) Types of COVID- 19 
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been fully vaccinated (figure 2), with Guinea, Ghana, 
Togo and Cape Verde having the highest proportions of 
their populations being fully vaccinated at 1.3%, 1.2%, 
0.9% and 0.5% of the total population, respectively. Côte 
d’Ivoire, Burkina Faso and Liberia had the lowest propor-
tions (0.01%, 0.02% and 0.05%) of their population fully 
vaccinated after three months of the vaccine deployment 
(figure 2B).
If the ECOWAS countries follow the speed of vaccination 
and/or the trajectory of the population fully vaccinated at 
0.27% after three months, the sub- region will be well below 
1.6% of the total population to receive full vaccination after 
18 months of commencement of the vaccinations (figure 3). 
To achieve a COVID- 19 vaccination coverage of at least 60% of 
the total population in West Africa at 9, 12 and 18 months after 
deployment of the vaccines, the speed of vaccination must be 
increased to 10, 7 and 4 times of the current trajectory, respec-
tively. A similar increase in rate is also needed at the country 
levels to ensure 60% of the total population is fully vaccinated 
at 9, 12 and 18 months after vaccine deployment (figure 4).
Table 1 Country- level background characteristics related to COVID- 19 vaccines and COVID- 19 epidemiology at the time of 




No of COVID- 19 
vaccines doses 
initially received
Arrival of vaccines to 
deployment duration 
(days)
COVID- 19 cases per 
100 000 population as of 
vaccine arrival
COVID deaths per 100 
000 population as of 
vaccine arrival
Benin 12 451 000 144 000 18 55 0.47
Burkina Faso 21 497 000 115 200 3 66 0.33
Cape Verde 556 000 24 000 6 2907 528.6
Côte d’Ivoire 27 054 000 504 000 3 126 0.49
Gambia 2 487 000 36 000 7 201 8.55
Ghana 31 732 000 600 000 5 267 0.88
Guinea 13 497 000 194 400 20 164 1.28
Guinea- Bissau 2 015 000 28 800 21 192 9.97
Liberia 5 180 000 396 000 27 45 0.96
Mali 20 856 000 44 286 15 54 0.29
Niger 25 131 000 400 000 7 23 0.11
Nigeria 211 401 000 3 924 000 2 66 0.03
Senegal 17 196 000 200 000 5 195 1.20
Sierra Leone 8 141 000 200 000 25 49 0.63
Togo 8 478 000 156 000 2 94 1.16
This table shows the total population of each of ECOWAS countries according to the UN Population Prospects 2020, number of 
COVID- 19 vaccines doses initially received in the first shipments, duration of arrival of vaccines in the country to vaccine deployment, 
COVID- 19 cases per 100 000 population and COVID deaths per 100 000 population as of vaccine arrival.
*Based on the UN Population Prospects 2020.
ECOWAS, Economic Community of West Africa States.
Figure 2 Cartographic representations of the COVID- 19 vaccination coverage in 15 ECOWAS countries showing the 
proportion of people (A) who received at least one dose and (B) who received two (full) doses of the vaccine, 3 months after 
deployment. ECOWAS, Economic Community of West Africa States.
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INTERPRETATIONS OF THE FINDINGS
Shipment of COVID- 19 vaccines to West African countries 
started as early as February 2021, barely two months after 
the vaccine roll- out in HICs. The relatively early shipment 
of COVID- 19 vaccines to West Africa inspired the belief 
that COVAX initiative might achieve its intended objec-
tives. However, the novel initiatives aimed at achieving 
equitable access to COVID- 19 vaccines by LMICs have 
been hampered by vaccine nationalism and hoarding 
by wealthy countries, export restrictions and difficulty 
in scaling- up production,20 which affected the Johnson 
& Johnson and AstraZeneca vaccines. Other challenges 
included delays in obtaining Emergency Use Authorisa-
tion approvals from the WHO by candidate vaccines such 
as Novavax, SII- Novavax, and Clover, lack of funds and 
readiness at the country level.21 Also, the Serum Institute 
of India, a key supplier for the COVAX initiative, halted 
vaccine exports due to an overwhelming outbreak of 
COVID- 19 in India, requiring the company to be able to 
meet the enormous local needs.20 This national action 
severely limited the production and delivery of Astra-
Zeneca vaccines for international use, with significant 
negative impact especially felt in West African countries 
with limited alternative sources of the vaccine supply.
Overall, COVID- 19 vaccination rates across West 
African countries remain very low after at least three 
months of deployment of the vaccines, as only 0.27% of 
the population have been fully vaccinated, compared with 
other African sub- regions such as Southern and North 
Africa where higher proportions of the populations were 
vaccinated during the same period, despite receiving a 
proportional supply of the COVID- 19 vaccine doses.6 17 22 
It is inappropriate to generalise the whole of Africa as 
having a young population, with a huge proportion in 
the informal sector with high unemployment rates, polit-
ical instability, insecurity and limited trust in government 
as factors impacting negatively on COVID- 19 vaccine 
uptake.23 Nevertheless, it is important to highlight the 
contextual peculiarities accounting for the deficient 
uptake in West Africa compared with other sub- regions 
in Africa, given its grave implication on the COVID- 19 
epidemiology, vis- a- vis emergence of COVID- 19 variants, 
increasing morbidity and mortality, social and economic 
losses for West African countries and similar environ-
ments with sub- optimal immunisation coverage.
The need to pre- position massive vaccine storage and 
delivery capacity (fast and slow cold chain equipment) 
powered by clean energy across all levels of vaccine 
supply management systems in most West African coun-
tries may explain the time lag between vaccine arrival 
and delivery to end- users. Also, the limited number of 
delivery points due to a shortage of funding for staffing 
and health infrastructures has likely contributed to 
the sub- optimal uptake of COVID- 19 vaccines.9 10 One 
approach that could address the limited number of 
points of vaccination service delivery and improve uptake 
is integration of COVID- 19 vaccination into the routine 
immunisation schedule.24 Although an inadequate 
Figure 3 The projected trajectory to achieve full vaccination in 50%, 60% and 70% of the population after 9, 12 and 18 
months of vaccine deployment in west Africa.
 on D
ecem









ealth: first published as 10.1136/bm






6 Afolabi MO, et al. BMJ Global Health 2021;6:e007518. doi:10.1136/bmjgh-2021-007518
BMJ Global Health
supply of vaccines could challenge this approach, concur-
rent delivery of COVID- 19 vaccines with Expanded 
Programme on Immunisation (EPI) vaccines in health 
facilities providing routine immunisations in the sub- 
region will obviate additional costs such as human 
resources and logistics.25 For example, the COVID- 19 
vaccination programme is being challenged in Nigeria 
by limited logistics including insufficient data bundle for 
electronic data management and inadequate funding for 
vaccination teams’ mobility.26 The Ivorian government 
Figure 4 The projected trajectory to achieve full vaccination in 50%, 60%, and 70% of the population after 9, 12 and 18 
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deployed mobile clinics and medically equipped buses to 
the busiest areas to raise awareness, educate and deliver 
COVID- 19 vaccines, which improved the uptake of the 
vaccines in the urban settlements.27 However, this was too 
little to significantly change the national vaccination rate 
amidst vaccine shortage. The downside of this approach 
is the huge financial and logistical requirements for its 
implementation.
Our analysis suggests that the ECOWAS region can 
achieve the COVID- 19 vaccination coverage of at least 
60% of the total population after 9, 12 and 18 months of 
the vaccine deployment by increasing the current vacci-
nation rates by 10, 7 and 4 times, respectively. This calls 
for prioritisation of access to vaccines by national govern-
ments of ECOWAS countries through adequate emer-
gency funding provisions for more bilateral agreements 
with vaccine manufacturers in order to complement 
the COVAX initiatives and the AVATT of the African 
Union. African countries with strong financial powers 
to preorder COVID- 19 vaccines fared better in terms 
of vaccination rates than West African countries that 
relied heavily or solely on the COVAX and the AVATT. 
The WHO- led COVAX initiative and African Union 
Task Team hope to achieve the delivery of 720 million 
doses of COVID- 19 vaccines to attain a target coverage 
of 60% by June 2022.15 This commitment was premised 
on initial epidemiological risk assessments, which did not 
take into account the changes in the epidemiology of the 
infection, for example, increasing infection in children 
being reported and the viral behaviour. This realisation 
implies a need to vaccinate other segments of the popu-
lation, thus providing greater population immunisation 
coverage. To address the challenge of vaccine hesitancy 
currently encountered in the COVID- 19 vaccination 
programmes in the West African sub- region,28 national 
governments and partners need to adopt culturally 
acceptable, community- led strategies to implement effec-
tive messaging that highlights the risks and benefits of 
vaccination, addresses the myths and misconceptions 
about COVID- 19 vaccinations.29 For example, in Côte 
d’Ivoire, the political leadership enlisted community 
influencers, religious and community leaders to address 
vaccine hesitancy.16 Adopting this strategy in all ECOWAS 
countries would improve vaccination uptake and reduce 
the time lag between the arrival of vaccines and vaccine 
delivery.
Given that public trust, confidence and acceptance 
of vaccinations can be enhanced if clinical trials that 
demonstrate a vaccine’s efficacy and safety are under-
taken locally,30 the calls for the conduct of more clinical 
trials and local manufacturing of COVID- 19 vaccines in 
the West African sub- region remain strident and crit-
ically germane. Beyond the advantage of access to life- 
saving vaccines, there are potential secondary benefits of 
vaccine research and development and local manufac-
turing capacities such as reduced or no cost of importa-
tion, less cold chain requirements and economic benefits 
to the host country. Establishment of this platform would 
also be useful for research and development for other 
vaccines targeted at diseases of public health importance 
in the region—Ebola, Lassa, cholera, meningococcal 
meningitis, and recently, Marburg.
Our analysis has a few limitations. The analysis focused 
on the first 90 days after deployment of COVID- 19 
vaccines. Following the shipment of the first batches of 
COVID- 19 vaccines by COVAX and subsequent roll- outs 
in West African countries, there was a huge gap in the 
shipment of subsequent supplies, and the vaccination 
rates declined dramatically. The re- commencement of 
the vaccine shipments in July 2021 has not significantly 
changed the vaccine performance and uptake across 
West African countries; hence, our analysis still reflects 
the prevailing situations of COVID- 19 vaccination imple-
mentations in West Africa. Also, we adopted simple linear 
interpolations of the vaccination trajectory. Although, 
the trajectories may deviate from linearity in some coun-
tries, these average trajectories allow much needed 
simplicity (over complex mathematical models) while 
providing reasonable estimates for the rate of vaccine 
coverage required to achieve targeted levels at specified 
time points.
CONCLUSION
The COVID- 19 vaccination coverage in the 15 ECOWAS 
member states was very low, three months after the 
vaccine deployment. The West African governments need 
to deploy contextually relevant and culturally acceptable 
strategies for COVID- 19 vaccine procurements, distri-
butions and implementations to improve the meagre 
COVID- 19 vaccination rates and achieve reasonable 
coverage to save lives, sooner rather than later.
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